How bacteria adhere to cells: Basis for the development of a new class of antibiotics

Adhesion of Bartonella henselae (blue) to human blood vessel cells (red). The bacterium’s adhesion to the host cells could be blocked with the help of what are known as “anti-ligands”.
(Photo Credit)

Researchers from University Hospital Frankfurt and Goethe University Frankfurt have unravelled how bacteria adhere to host cells and thus taken the first step towards developing a new class of antibiotics.

The adhesion of bacteria to host cells is always the first and one of the decisivesteps in the development of infectious diseases. The purpose of this adhesion by infectious pathogens is first to colonize the host organism (i.e., the human body), and then to trigger an infection, which in the worst case can end fatally. Precise understanding of the bacteria’s adhesion to host cells is a key to finding therapeutic alternatives that block this critical interaction in the earliest possible stage of an infection.

Critical interaction with the human protein fibronectin

In collaboration with other researchers, scientists from University Hospital Frankfurt and Goethe University Frankfurt have now explained the exact bacterial adhesion mechanism using the human-pathogenic bacterium Bartonella henselae. This pathogen causes “cat-scratch disease”, a disease transmitted from animals to humans. In an international collaborative project led by the Frankfurt research group headed by Professor Volkhard Kempf, the bacterial adhesion mechanism was deciphered with the help of a combination of in-vitro adhesion tests and high-throughput proteomics. Proteomics is the study of all the proteins present in a cell or a complex organism.

The scientists have shed light on a key mechanism: the bacterial adhesion to the host cells can be traced back to the interaction of a certain class of adhesins – called “trimeric autotransporter adhesins” – with fibronectin, a protein often found in human tissue. Adhesins are components on the surface of bacteria which enable the pathogen to adhere to the host’s biological structures. Homologues of the adhesin identified here as critical are also present in many other human-pathogenic bacteria, such as the multi-resistant Acinetobacter baumannii, which the World Health Organization (WHO) has classified as the top priority for research into new antibiotics.

State-of-the-art protein analytics were used to visualize the exact points of interaction between the proteins. In addition, it was possible to show that experimental blocking of these processes almost entirely prevents bacterial adhesion. Therapeutic approaches that aim to prevent bacterial adhesion in this way could represent a promising treatment alternative as a new class of antibiotics (known as “anti-ligands”) in the constantly growing domain of multi-resistant bacteria.

Prestigious funding

The research work was funded as part of an Innovative Training Network (“ViBrANT: Viral and Bacterial Adhesin Network Training”) under the Marie Skłodowska-Curie Actions (MSCA) of the European Union’s HORIZON 2020 research and innovation programme.

The scientific paper has been published in the prestigious journal “Microbiology Spectrum” of the American Society of Microbiology (ASM) and was acknowledged as “Paper of the Month” by the German Society for Hygiene and Microbiology (DGHM) on 18 June 2022.

Publication: Vaca, D. J., Thibau, A., Leisegang, M. S., Malmström, J., Linke, D., Eble, J. A., Ballhorn, W., Schaller, M., Happonen, L., Kempf, V. A. J.; Interaction of Bartonella henselae with Fibronectin Represents the Molecular Basis for Adhesion to Host Cells; Microbiology Spectrum, 18 April, 2022. https://doi.org/10.1128/spectrum.00598-22

Relevante Artikel

Roland Hardenberg, Foto: Jennifer Markwirth

100 Jahre Frobenius-Institut in Frankfurt

Internationales Zentrum für kulturanthropologische Forschung feiert Jubiläum Das Frobenius-Institut für kulturanthropologische Forschung an der Goethe-Universität ist mit seinen Archiven und

Dr. Ah Jung Heo, Postdoc im Labor Đikic, forscht daran, wie krankheitsrelevante Proteine gezielt abgebaut werden könnten. Foto: Peter Kiefer

Krankmacher gezielt entsorgen

Wie durch Umprogrammierung von Zellen schädliche Proteine abgebaut und Krankheiten bekämpft werden können Das kleine Protein Ubiquitin kommt in den

Das Collier mit dem sprechenden Titel »Engineered Antibody« von 2016. Foto: Foto: Anna Dumitriu

Antibody amulets

Anna Dumitriu’s biotech jewelry A glittering, heart-shaped gold pendant set with sapphires on a wide bow of cream-colored silk as

Das Collier mit dem sprechenden Titel »Engineered Antibody« von 2016. Foto: Foto: Anna Dumitriu

Antikörper-Amulette

Biotech-Schmuck von Anna Dumitriu Ein herzförmiger, mit Saphiren besetzter goldglänzender Anhänger an einer breiten Schleife aus cremefarbener Seide, die um

Öffentliche Veranstaltungen
Roland Hardenberg, Foto: Jennifer Markwirth

100 Jahre Frobenius-Institut in Frankfurt

Internationales Zentrum für kulturanthropologische Forschung feiert Jubiläum Das Frobenius-Institut für kulturanthropologische Forschung an der Goethe-Universität ist mit seinen Archiven und

Dr. Ah Jung Heo, Postdoc im Labor Đikic, forscht daran, wie krankheitsrelevante Proteine gezielt abgebaut werden könnten. Foto: Peter Kiefer

Krankmacher gezielt entsorgen

Wie durch Umprogrammierung von Zellen schädliche Proteine abgebaut und Krankheiten bekämpft werden können Das kleine Protein Ubiquitin kommt in den

Das Collier mit dem sprechenden Titel »Engineered Antibody« von 2016. Foto: Foto: Anna Dumitriu

Antikörper-Amulette

Biotech-Schmuck von Anna Dumitriu Ein herzförmiger, mit Saphiren besetzter goldglänzender Anhänger an einer breiten Schleife aus cremefarbener Seide, die um

Wie Medikamente sehen die Kapseln aus, über die Patienten »gute« Bakterien zu sich nehmen, die Krankheitserreger im Darm verdrängen können. Foto: AG Maria Vehreschild

Therapie mit Bakterien

Wie »gute« Darmbakterien gefährliche Erreger bekämpfen könnten Dank Antibiotika haben bakterielle ­Infektionen ihren Schrecken weitgehend verloren. Für Menschen mit geschwächtem

You cannot copy content of this page